Budget 2026 | Biopharma SHAKTI: The scheme sits at the intersection of public health imperatives and industrial policy.

The long-held expectation that the global market for obesity drugs would reach $150 billion in the next decade is looking a ...

Plan includes 1000 clinical trial sites, stronger drug regulator, higher electronics outlay, and focus on equipment materials ...

OPPI sees 2026 as a decisive step towards global biopharma manufacturing leadership: Our Bureau, Bengaluru Monday, February 2, 2026, 11:30 Hrs [IST] Organisation of Pharmaceutical ...

The Budget acknowledges the growing burden of non-communicable diseases such as cancer, diabetes and autoimmune disorders, alongside the increasing global reliance on biologic medicines.

The Union Budget's focus on biopharma is poised to enhance India's pharmaceutical innovation and research capabilities ...

Finance Minister Nirmala Sitharaman announces Biopharma Shakti, a ₹10,000 crore plan to boost biologics, biosimilars, ...

Union Budget 2026: With the announcement of the 'Biopharma Shakti' initiative, India is gearing up to take the world stage in ...

Industry leaders have said the Union Budget 2026 has laid the groundwork for a major shift in India's pharmaceutical sector, with the Biopharma SHAKTI initiative expected to reduce reliance on ...

The Union Budget presented by Finance Minister Nirmala Sitharaman in Parliament on Sunday on healthcare and pharmaceuticals ...

BENGALURU: The Union Budget has placed biopharmaceutical development at the centre of India’s healthcare strategy, with ...

Finance Minister Nirmala Sitharaman, in her budget speech, unveiled “Biopharma Shakti”, a ₹10,000-crore strategy aimed at ...